Background
- Lowgrade ovarian(OC) and endometrial(EC) cancers frequently express estrogen receptor (ERα,encodedbyESR1), and are considered hormonally responsive tumors.
- The use of endocrine therapy in the advanced and recurrent disease setting is common.
- Mechanisms for endocrine therapy failure in gynecologic cancers are not well understood.
- In breast cancer, ESR1 mutations (ESR1mt) confer resistance to endocrine therapy.
- In this study, we aim to evaluate the prevalence of ESRmt, and associated characteristics in OC and EC.